Notes, commentary and analysis on retinal disease, gene and cell therapy and the business of bringing new treatments to patients.

A place for Professor Fischer’s thinking on the developments shaping the field, written for the people making decisions in it. Clinical developments, trial readouts, regulatory shifts and the commercial questions that follow.